Esperion Therapeutics Inc.
ESPR
NSD
Sector: Healthcare
Industry: Biotechnology
6.10
USD
0.18
(3.04%)
Optionable: Yes Market Cap: 370 M 90-day average vol: 859,344
Previous close: 5.92 Open: 5.82 Bid: 6.19 Ask: 6.19
52 week range
3.28 14.78
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 7.60 |
Price per Book TTM ($) | 80.52 |
PE Ratio (TTM) | -0.80 |
Book Value per Share ($) | -12.02 |
5 Year PE Range | -15.8 , -5.4 |
Returns
7 Day Return | 11.93% | |
1 Month Return | -8.55% | |
3 Month Return | 14.45% | |
1 Year Return | -56.52% | |
3 Year Return | -84.37% | |
5 Year Return | -88.30% | |
YTD Return | 22.00% |
Risk
Custom Beta One Year | 1.10 |
Custom Beta Three Years | 1.07 |
Beneish M Score | 331.19 |
Altman Z Score | -4.58 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 49.61 |
14 Day SMA ($) | 6.09 |
14 Day EMA ($) | 6.05 |
Money Flow Index | 30.70 |
Average True Range | 0.40 |
50 Day SMA ($) | 6.06 |
200 Day SMA ($) | 5.78 |
ADX | 54.62 |
MACD | -0.10 |
Growth
Free Cash Flow QoQ Growth | -32.43% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -47.46% |
Revenue QoQ Growth | 22.30% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
Yahoo Finance 2/24/2022
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%
Yahoo Finance 2/23/2022
Esperion Therapeutics, Inc. (ESPR) CEO Sheldon Koenig on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/22/2022
Esperion Therapeutics (ESPR) Q4 2021 Earnings Call Transcript
Yahoo Finance 2/22/2022
Esperion stock rises 12% as FY21 net product sales soar 209% Y/Y
Seeking Alpha 2/22/2022
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance 2/22/2022
Esperion Therapeutics GAAP EPS of -$1.77 beats by $0.52, revenue of $15.4M beats by $0.92M
Seeking Alpha 2/22/2022
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Yahoo Finance 2/22/2022
Esperion Therapeutics Q4 2021 Earnings Preview
Seeking Alpha 2/18/2022
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Yahoo Finance 2/15/2022
Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
Yahoo Finance 2/8/2022
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Yahoo Finance 1/28/2022
Esperion Therapeutics - A Glimmer Of Light At The End Of The Tunnel
Seeking Alpha 1/21/2022
Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022
Seeking Alpha 1/20/2022
Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update
Yahoo Finance 1/11/2022
Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference
Yahoo Finance 1/6/2022
Meditor Group Ltd Buys Esperion Therapeutics Inc, Sells BTC iShares MSCI India ETF, WisdomTree ...
Yahoo Finance 1/5/2022
What Type Of Shareholders Own The Most Number of Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares?
Yahoo Finance 1/5/2022
Esperion Appoints Benjamin O. Looker as General Counsel
Yahoo Finance 1/4/2022
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 2.345
Financials
ESPR Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 148 M | 228 M | 78 M |
| Cost of sales | -139000 | -118000 | -362000 | -883000 | -1 M | -592000 | -48000 | -119000 | 2 M | 14 M |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 148 M | 225 M | 64 M |
| Selling Gen & administrative expense | 2 M | 7 M | 11 M | 20 M | 18 M | 21 M | 33 M | 66 M | 200 M | 185 M |
| Research & development expense | 8 M | 16 M | 25 M | 30 M | 58 M | 148 M | 171 M | 176 M | 147 M | 106 M |
| Operating income | -10 M | -23 M | -36 M | -50 M | -76 M | -169 M | -205 M | -93 M | -121 M | -227 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | -52000 | -2 M | 119000 | 776000 | 2 M | 2 M | 3 M | 4 M | 515000 | 4 M |
| Pre-tax Income (EBT) | -12 M | -26 M | -36 M | -50 M | -75 M | -167 M | -202 M | -97 M | -144 M | -269 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from total operations | -12 M | -26 M | -36 M | -50 M | -75 M | -167 M | -202 M | -97 M | -144 M | -269 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -12 M | -26 M | -36 M | -50 M | -75 M | -167 M | -202 M | -97 M | -144 M | -269 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -12 M | -26 M | -36 M | -50 M | -75 M | -167 M | -202 M | -97 M | -144 M | -269 M |
| Depreciation | 139000 | 118000 | 362000 | 883000 | 1 M | 592000 | 48000 | 119000 | 450000 | 624000 |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -10 M | -25 M | -36 M | -49 M | -74 M | -167 M | -202 M | -89 M | -120 M | -222 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -21.87 | -3.31 | -2.22 | -2.26 | -3.33 | -6.98 | -7.54 | -3.59 | -5.23 | -9.31 |
| Diluted EPS total | -21.87 | -3.31 | -2.22 | -2.26 | -3.33 | -6.98 | -7.54 | -3.59 | -5.23 | -9.31 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!